MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00401-025-02894-3

Медицинская библиотека · Acta neuropathologica · 2025

Outcome-associated factors in a molecularly defined cohort of central neurocytoma.

Krech Maja, Muench Amos, Teichmann Daniel, Kuzman Peter, Suwala Abigail K, Ippen Franziska M, Müther Michael, Weber Katharina J, Wenger-Alakmeh Katharina, Onken Julia, Vajkoczy Peter, Behling Felix, May Sven-Axel, Ntoulias Georgios, Krauss Joachim K, Atallah Oday, Esmaeilzadeh Majid, Mueller Wolf C, Heppner Frank L, Radbruch Helena, Dittmayer Carsten, Stenzel Werner, Koch Arend, Capper David, Kaul David, Paulus Werner, Plate Karl H, Steinbach Joachim P, Czabanka Markus, Beschorner Rudi, von Deimling Andreas, Bockmayr Michael, Neumann Julia E, Brandner Sebastian, Krieger Teresa, Hartmann Christian, Thomas Christian, Schweizer Leonille

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Central neurocytomas (CN) are intraventricular brain tumors predominantly occurring in young adults. Although prognosis is usually favorable, tumor recurrence is common, particularly following subtotal resection (STR). Currently, the risk of progression is evaluated using atypical features and an elevated Ki67 proliferation index. However, these markers lack consistent definitions, raising the need for objective criteria. Genome-wide DNA methylation profiles were examined in 136 tumors histologically classified as CN. Clinical/histopathological characteristics were assessed in 93/90 cases, and whole-exome sequencing was conducted in 12 cases. Clinical and molecular characteristics were integrated into a survival model to predict progression-free survival (PFS). A diagnosis of CN was epigenetically confirmed in 125 of 136 cases (92%). No DNA methylation subgroups were identified, but global DNA hypomethylation emerged as a hallmark feature of CN associated with higher recurrence risk. Risk stratification based on histological features of atypia and Ki67 proliferation index was not reproducible across neuropathologists. Hypomethylation at the FGFR3 locus, accompanied by increased FGFR3 protein expression, was observed in 97% of cases. Gross total resection was associated with significantly improved PFS compared to STR, while patients undergoing STR receiving radiotherapy had a better outcome (p = 0.0001). Younger patients were identified as having a higher risk of recurrence (p = 0.026). Patient age and treatment strategy were key factors associated with survival outcomes in this cohort. These findings underscore the importance of closer follow-up for younger patients and radiotherapy for STR cases. Furthermore, FGFR3 represents a hallmark feature and potential therapeutic target, warranting further investigation.

Для цитирования: Krech Maja, Muench Amos, Teichmann Daniel, Kuzman Peter, Suwala Abigail K, Ippen Franziska M, Müther Michael, Weber Katharina J, Wenger-Alakmeh Katharina, Onken Julia, Vajkoczy Peter, Behling Felix, May Sven-Axel, Ntoulias Georgios, Krauss Joachim K, Atallah Oday, Esmaeilzadeh Majid, Mueller Wolf C, Heppner Frank L, Radbruch Helena, Dittmayer Carsten, Stenzel Werner, Koch Arend, Capper David, Kaul David, Paulus Werner, Plate Karl H, Steinbach Joachim P, Czabanka Markus, Beschorner Rudi, von Deimling Andreas, Bockmayr Michael, Neumann Julia E, Brandner Sebastian, Krieger Teresa, Hartmann Christian, Thomas Christian, Schweizer Leonille. Outcome-associated factors in a molecularly defined cohort of central neurocytoma.. Acta neuropathologica. 2025. DOI: 10.1007/s00401-025-02894-3.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.